Rabies Infection Pipeline Insight 2025: Monoclonal Antibodies, Novel Vaccines, and Antiviral Platforms Drive Innovation

The rabies infection pipeline is rapidly advancing, with novel approaches aiming to improve prevention and post-exposure care. Despite the effectiveness of current post-exposure prophylaxis (PEP) with vaccines and immunoglobulin, limited access, high costs, and a lack of treatment for symptomatic cases underscore a significant unmet need. The therapeutic pipeline is driven by the development of recombinant monoclonal antibody cocktails, next-generation vaccines, and antiviral platforms.

Key Takeaways:

• DelveInsight's rabies infection pipeline analysis features a strong presence of 10+ active players working on 10+ pipeline drugs for rabies infection treatment.
• Key rabies infection companies include Synermore Biologics, Sanofi, Anhui Zhifei Longcom Biopharmaceutical, CureVac AG, Yisheng Biopharma, GlaxoSmithKline, and others, evaluating their lead assets to improve the rabies infection treatment landscape.
• Key rabies infection pipeline therapies in various stages of development include SYN023, Purified vero rabies vaccine, Freeze-dried Human Rabies Vaccine, CV7201, PIKA rabies vaccine, GSK 3903133A, Rabies G protein vaccine, IMT504, and others.
• SYN023, developed by Synermore Biologics, is a combination of two humanized monoclonal antibodies that target two distinct antigenic sites on the rabies glycoprotein, aimed for post-exposure prophylaxis in humans alongside the rabies vaccine.
• Freeze-dried human rabies vaccine, developed by Anhui Zhifei Longcom Biopharmaceutical, utilizes Vero cells and is also in Phase III development for rabies treatment.

Statistics:

• As of April 2025, DelveInsight's tracking data highlights 274 active players working on 223 pipeline drugs for rabies infection treatment, showing a significant increase from the last update in January 2025, where 237 active players were identified.
• The freeze-dried human rabies vaccine, developed by Anhui Zhifei Longcom Biopharmaceutical, demonstrated an immune response comparable to that seen with the standard rabies vaccine in a preclinical study of 60 guinea pigs.
• SYN-023 has demonstrated the ability to neutralize over 15 contemporary rabies virus isolates from wildlife in China and 10 isolates from North America.

Sources:

• DelveInsight's "Rabies Infection - Pipeline Insight, 2025"
• https://www.delveinsight.com/report-store/rabies-infection-pipeline-insight
• M2 PressWIRE-August 15, 2025-
• https://www.abnewswire.com/pressreleases/rabies-infection-pipeline-insight-2025-monoclonal-antibodies-novel-vaccines-and-antiviral-platforms-drive-innovation-173021.html